|
Collaboration Agreement (Details) (USD $)
|
1 Months Ended | 3 Months Ended | 9 Months Ended | 1 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 9 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2009
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Mar. 21, 2012
|
Dec. 31, 2011
|
Dec. 31, 2009
TEVA Pharmaceutical Industries Ltd. [Member]
|
Sep. 30, 2012
TEVA Pharmaceutical Industries Ltd. [Member]
|
Sep. 30, 2012
Minimum [Member]
TEVA Pharmaceutical Industries Ltd. [Member]
|
Sep. 30, 2012
Maximum [Member]
TEVA Pharmaceutical Industries Ltd. [Member]
|
Sep. 30, 2012
Collaboration Agreement [Member]
|
Sep. 30, 2012
Collaboration Agreement [Member]
TEVA Pharmaceutical Industries Ltd. [Member]
|
Sep. 30, 2011
Collaboration Agreement [Member]
TEVA Pharmaceutical Industries Ltd. [Member]
|
Sep. 30, 2012
Collaboration Agreement [Member]
TEVA Pharmaceutical Industries Ltd. [Member]
|
Sep. 30, 2011
Collaboration Agreement [Member]
TEVA Pharmaceutical Industries Ltd. [Member]
|
Dec. 20, 2009
Collaboration Agreement [Member]
TEVA Pharmaceutical Industries Ltd. [Member]
|
Sep. 30, 2012
Collaboration Agreement [Member]
Minimum [Member]
TEVA Pharmaceutical Industries Ltd. [Member]
|
Sep. 30, 2012
Collaboration Agreement [Member]
Maximum [Member]
TEVA Pharmaceutical Industries Ltd. [Member]
|
|
| Collaboration Agreement (Textual) [Abstract] | |||||||||||||||||||
| Collaboration agreement aggregate amount | $ 50,000,000 | $ 50,000,000 | |||||||||||||||||
| Maximum amount receivable | 370,000,000 | 370,000,000 | |||||||||||||||||
| Equity investment | 15,000 | 15,000 | 10,000 | 10,000,000 | 10,000,000 | ||||||||||||||
| Share premium | 20.00% | ||||||||||||||||||
| Common shares, purchase price | $ 12.00 | $ 37.38 | $ 37.38 | ||||||||||||||||
| Common shares purchased | 267,531 | ||||||||||||||||||
| Research and development | 12,895,000 | 3,814,000 | 24,303,000 | 14,076,000 | 10,000,000 | ||||||||||||||
| Payment related to license agreement | 300,000 | ||||||||||||||||||
| Percentage of milestone payments required to be paid to third party | 31.00% | ||||||||||||||||||
| Percentage of net sales required to be paid as royalty to third party | 4.88% | 8.00% | |||||||||||||||||
| Direct and indirect development costs | 30,000,000 | ||||||||||||||||||
| Period of authorization change | 90 days | ||||||||||||||||||
| Revenue | 6,600,000 | 1,200,000 | 10,300,000 | 4,300,000 | |||||||||||||||
| Deferred collaboration revenue | 9,100,000 | 9,100,000 | |||||||||||||||||
| Revenue reimbursable on cash basis | 600,000 | ||||||||||||||||||
| Royalties at percentage rates ranging | Mid-teens to mid-twenties on net sales | ||||||||||||||||||
| Terminate of collaboration agreement | 3 months | 6 months | |||||||||||||||||
| Expiration of royalties | 10 years | ||||||||||||||||||
| Royalty Expense | $ 0 | ||||||||||||||||||
| Collaboration Agreement (Additional Textual) [Abstract] | |||||||||||||||||||
| Average premium period | 30 days | ||||||||||||||||||